AGP Executive Report
Last update: 11 hours agoPatient Supply: The Netherlands’ sole licensed medicinal-cannabis grower, Bedrocan, has gone bankrupt after losing its state contract. Stocks may last until mid-2027, but patients could then rely on imports; a law allowing direct sales to pharmacies is not expected until 2028. Hemp and CBD Rules: U.S. federal restrictions on hemp-derived intoxicating products are looming, with key changes delayed until Dec. 11. A separate provision takes effect Nov. 12, classifying cannabinoids that cannot occur naturally in cannabis as marijuana. Industry estimates suggest many full-spectrum CBD products may fall outside the revised definition, though that estimate is not official. Medical Uses: New York regulators approved a trial of oral THC for sciatica-related chronic pain, while the FDA opened a conditional-approval pathway for a cannabinoid drug targeting canine bone-cancer pain. Maryland also passed a law limiting veterinary-board action against vets who discuss cannabis and CBD. Rescheduling: Federal marijuana rescheduling proceedings remain paused while a judge considers a new government report and additional filings.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![[Nov 2] Wildlife - Turkey Project Temporary Worker](https://www.iowadnr.gov/sites/default/files/styles/large/public/images/2025-12/News%20Employment%20Opportunity%20-%20Seasonal.png.webp?itok=dXWjWY44)
